FDA Inspection
Sunrise Pharmaceutical, Inc.Sunrise Pharmaceutical, Inc. – FDA Inspection, Jan 18, 2018
Record Details
This FDA Inspection record concerns Sunrise Pharmaceutical, Inc., with an inspection on January 18, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
- Person
- Yvesna C. Blaise (Issuing Officer)
View Company Profile
ID · cabee28d-5fdd-428d-be3a-b49f22ce0929
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1038016
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.25(a)GMP Training Frequency
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Sunrise Pharmaceutical, Inc.
8| Date | Classification | Office | Project area |
|---|---|---|---|
| March 31, 2026 | Not classified | New Jersey District Office | Drug Quality Assurance |
| January 27, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 22, 2017 | Not classified | New Jersey District Office | |
| April 6, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 8, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Sunrise Pharmaceutical, Inc.
- FDA Inspection 1310416 - 2026-03-31
- FDA Inspection 1198356 - 2023-01-27
- FDA Inspection 1016794 - 2017-06-22
- FDA Inspection 1013086 - 2017-04-06
- FDA Inspection 861922 - 2014-01-08
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.